<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966536</url>
  </required_header>
  <id_info>
    <org_study_id>Neofol2013</org_study_id>
    <nct_id>NCT01966536</nct_id>
  </id_info>
  <brief_title>CD133 Transplantation to Generate Oocytes in Poor Ovarian Reserve</brief_title>
  <official_title>CD133+ Autologue Transplantation to Promote Ovarian Follicles Development in Women With Poor Ovarian Reserve.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women delay maternity and, as a consequence, available oocyte number and their quality
      decrease (9-18% of all IVF patients). Different treatment protocols have been developped
      nevertheless none of them optimal: the number of oocytes retrieved depends on the present
      ones. New generation of oocytes and follicles has been defended by some authors and bone
      marrow seems to be involved. What seems crucial is the niche that produces paracrine signals
      able to activate dormant cells and to attract undifferentiated cells from other tissues
      (homing). This phenomenon has been described by our group in other human reproductive tissues
      like endometrium. The purpose of the study is to improve ovarian reserve in unfertile women
      with poor ovarian reserve by means of bone marrow protective capacity.

      CD133+ cells obtained from bone marrow will be delivered into the ovarian artery allowing
      them to colonize ovarian niche.

      The study hypothesis is that CD133+ cells will improve ovarian reserve differentiating
      themselves into germ cells or, more likely, stimulating the niche to activate dormant
      follicles.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to fundamental changes in procedures design no patients have been enrolled
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ovarian reserve</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by FSH-LH, oestradiol, AMH, antral follicle count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian response to stimulation for oocyte retrieval</measure>
    <time_frame>6 months</time_frame>
    <description>Number of MII oocytes obtained</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Poor ovarian reserve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous transplantation of CD133+ cells into ovarian artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CD133+ cells transplantation into ovarian artery of one ovary</intervention_name>
    <arm_group_label>Poor ovarian reserve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt; or= 40 years old

          -  FSH&lt;15UI/L

          -  poor ovarian response after controlled ovarian stimulation with conventional doses (&lt;3
             oocytes) or two episodes of poor ovarian response after ovarian stimulation with
             maximal doses even if young or normal ovarian reserve study.

          -  Antral follicle count&gt;2

          -  &gt;1 antral follicle in the perfunded ovary

          -  AMH between 0,5 and 1pmol/L

          -  regular menstrual bleeding each 21-35 days

          -  To be candidate to autologous hematopoietic progenitors transplantation

        Exclusion Criteria:

          -  Ovarian endometriosis

          -  Anovulation

          -  Any ovarian surgery considered risk factor of low ovarian response.

          -  Genetic factors associated to low ovarian response (Turner syndrome, FMR1
             mutations...)

          -  Adquired conditions determining low response (chemotherapy, radiotherapy...)

          -  BMI &gt; or = 30kg/m2

          -  Allergie to iodine

          -  Kidney failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Pellicer, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Munné S, Cohen J, Sable D. Preimplantation genetic diagnosis for advanced maternal age and other indications. Fertil Steril. 2002 Aug;78(2):234-6.</citation>
    <PMID>12137856</PMID>
  </reference>
  <reference>
    <citation>Garcia-Velasco JA, Isaza V, Requena A, Martínez-Salazar FJ, Landazábal A, Remohí J, Pellicer A, Simón C. High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. Hum Reprod. 2000 Nov;15(11):2292-6.</citation>
    <PMID>11056121</PMID>
  </reference>
  <reference>
    <citation>La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 Mar-Apr;16(2):113-30. doi: 10.1093/humupd/dmp036. Epub 2009 Sep 30. Review.</citation>
    <PMID>19793843</PMID>
  </reference>
  <reference>
    <citation>Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004 Mar 11;428(6979):145-50. Erratum in: Nature. 2004 Aug 26;430(7003):1062.</citation>
    <PMID>15014492</PMID>
  </reference>
  <reference>
    <citation>White YA, Woods DC, Takai Y, Ishihara O, Seki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. Nat Med. 2012 Feb 26;18(3):413-21. doi: 10.1038/nm.2669.</citation>
    <PMID>22366948</PMID>
  </reference>
  <reference>
    <citation>Johnson J, Bagley J, Skaznik-Wikiel M, Lee HJ, Adams GB, Niikura Y, Tschudy KS, Tilly JC, Cortes ML, Forkert R, Spitzer T, Iacomini J, Scadden DT, Tilly JL. Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell. 2005 Jul 29;122(2):303-15.</citation>
    <PMID>16051153</PMID>
  </reference>
  <reference>
    <citation>Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res. 2010 Jan 1;70(1):221-8. doi: 10.1158/0008-5472.CAN-09-3232. Epub 2009 Dec 22.</citation>
    <PMID>20028858</PMID>
  </reference>
  <reference>
    <citation>Eggan K, Jurga S, Gosden R, Min IM, Wagers AJ. Ovulated oocytes in adult mice derive from non-circulating germ cells. Nature. 2006 Jun 29;441(7097):1109-14. Epub 2006 Jun 14.</citation>
    <PMID>16799565</PMID>
  </reference>
  <reference>
    <citation>Li J, Kawamura K, Cheng Y, Liu S, Klein C, Liu S, Duan EK, Hsueh AJ. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10280-4. doi: 10.1073/pnas.1001198107. Epub 2010 May 17.</citation>
    <PMID>20479243</PMID>
  </reference>
  <reference>
    <citation>Bhartiya D, Sriraman K, Parte S. Stem cell interaction with somatic niche may hold the key to fertility restoration in cancer patients. Obstet Gynecol Int. 2012;2012:921082. doi: 10.1155/2012/921082. Epub 2012 Apr 2.</citation>
    <PMID>22548074</PMID>
  </reference>
  <reference>
    <citation>Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA. 2004 Jul 7;292(1):81-5.</citation>
    <PMID>15238594</PMID>
  </reference>
  <reference>
    <citation>Nagori CB, Panchal SY, Patel H. Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Asherman's syndrome. J Hum Reprod Sci. 2011 Jan;4(1):43-8. doi: 10.4103/0974-1208.82360.</citation>
    <PMID>21772740</PMID>
  </reference>
  <reference>
    <citation>Gargett CE, Healy DL. Generating receptive endometrium in Asherman's syndrome. J Hum Reprod Sci. 2011 Jan;4(1):49-52.</citation>
    <PMID>21772741</PMID>
  </reference>
  <reference>
    <citation>Zeng H, Li L, Chen JX. Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One. 2012;7(4):e35905. doi: 10.1371/journal.pone.0035905. Epub 2012 Apr 27.</citation>
    <PMID>22558265</PMID>
  </reference>
  <reference>
    <citation>Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature. 2013 Mar 14;495(7440):241-5. doi: 10.1038/nature11979. Epub 2013 Mar 6.</citation>
    <PMID>23467088</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2013</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Fe</investigator_affiliation>
    <investigator_full_name>Dr. Antonio Pellicer Martínez</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

